For example, growth factor receptors may be overexpressed and accessible at the membrane of tumor cells, so antibodies targeting growth factor receptors may be used, such as the anti-epidermal growth factor receptor (EGFR) antibody (cetuximab) [262] or trastuzumab (anti-ERBB2, Herceptin®). This evidence concerns the gene EGFR and neoplasm.